OverviewSuggest Edit

Syneos Health (formerly known as INC Research) is a contract research organization that provides various clinical development services for the biopharmaceutical and medical device industries. Its operations are divided into two segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers a variety of services spanning clinical development, including clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.

TypePublic
Founded1998
HQMorrisville, NC, US
Websitesyneoshealth.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2020)25,000(+5%)
Job Openings1,851
Revenue (FY, 2020)$4.4 B(-5%)
Share Price (Sept 2021)$93.7(-1%)
Cybersecurity ratingCMore

Key People/Management at Syneos Health

Alistair Macdonald

Alistair Macdonald

Chief Executive Officer
Jason Meggs

Jason Meggs

Chief Financial Officer
Neil Ferguson

Neil Ferguson

Chief Business Officer
Michelle Keefe

Michelle Keefe

President, Commercial Solutions
Lisa van Capelle

Lisa van Capelle

Chief Human Resources Officer
Paul Colvin

Paul Colvin

President, Clinical Solutions
Show more

Syneos Health Office Locations

Syneos Health has offices in Morrisville, Austin, Blue Bell, Boston and in 77 other locations
Morrisville, NC, US (HQ)
1030 Sync St
Austin, TX, US
Encino Trace Building II, 5707 Southwest Parkway, Suite 200
Blue Bell, PA, US
1787 Sentry Pkwy W Building 18, Suite 300
Boston, MA, US
470 Atlantic Ave 11th floor
Charlotte, NC, US
11525 N. Community House Road
Irvine, CA, US
2525 Main Street #300
Show all (88)

Syneos Health Financials and Metrics

Syneos Health Revenue

Embed Graph
View revenue for all periods
Syneos Health's revenue was reported to be $4.42 b in FY, 2020 which is a 5.6% decrease from the previous period.
USD

Revenue (Q1, 2021)

1.2b

Gross profit (Q1, 2021)

263.5m

Gross profit margin (Q1, 2021), %

21.8%

Net income (Q1, 2021)

38.7m

EBIT (Q1, 2021)

61.0m

Market capitalization (15-Sept-2021)

9.6b

Closing stock price (15-Sept-2021)

93.7

Cash (31-Mar-2021)

264.7m

EV

12.5b
Syneos Health's current market capitalization is $9.6 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

4.4b4.7b4.4b

Revenue growth, %

64%7%(6%)

Cost of goods sold

3.4b3.6b3.4b

Gross profit

955.8m1.0b1.0b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.1b1.2b1.2b1.2b1.0b1.1b1.2b

Cost of goods sold

886.8m917.5m913.7m924.0m805.9m820.2m945.3m

Gross profit

232.2m249.3m263.4m239.3m207.5m278.8m263.5m

Gross profit Margin, %

21%21%22%21%20%25%22%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

155.9m163.7m272.2m

Accounts Receivable

1.3b1.3b1.3m

Current Assets

1.5b1.6b1.7b

PP&E

183.5m203.9m216.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

107.9m107.3m129.2m336.0m343.0m248.9m264.7m

Accounts Receivable

1.2b1.3b1.3b1.3b1.2b1.3b

Prepaid Expenses

110.5m

Current Assets

1.4b1.5b1.5b1.8b1.6b1.6b1.7b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

24.3m131.3m192.8m

Depreciation and Amortization

273.7m242.5m222.4m

Accounts Payable

60.0m28.3m(2.6m)

Cash From Operating Activities

303.4m318.5m425.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(30.0m)(18.7m)40.2m33.6m37.5m100.9m38.7m

Depreciation and Amortization

61.2m121.9m182.1m56.1m112.1m167.6m57.9m

Accounts Payable

(26.7m)32.0m12.3m(66.4m)(64.8m)(2.2m)518.0k

Cash From Operating Activities

(13.3m)83.5m157.9m(38.6m)155.2m311.2m127.1m
USDFY, 2018

EV/EBIT

42 x

EV/CFO

22.2 x

Revenue/Employee

182.9k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.5 x

P/E Ratio

171.1
Show all financial metrics

Syneos Health Operating Metrics

Syneos Health's Backlog was reported to be $11b in FY, 2020.
FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020FY, 2020

Countries

474149

Facilities

120110130

Backlog

$4.86 b$7.33 b$8.46 b$8.38 b$8.9 b$9.21 b$9.61 b$9.78 b$10.95 b

Backlog (Clinical Solutions)

$4.32 b$7.61 b$7.83 b$7.78 b$8.22 b$8.55 b$9 b$9.2 b$10.24 b
Show all operating metrics

Syneos Health Acquisitions / Subsidiaries

Company NameDateDeal Size
KinapseAugust 20, 2018
inVentiv Health, Inc.May 10, 2017$4.6 b
Kendle International Inc.May 04, 2011$232 m
inChord Holding Corporation (US)
INC Research Europe
INC Research Holding
INC Research II LP
INC Research International Holdings
inVentiv Clinical UK Entities
inVentiv Commercial Services, LLC
Show more

Syneos Health Revenue Breakdown

Embed Graph

Syneos Health revenue breakdown by business segment: 73.2% from Clinical Solutions, 24.6% from Commercial Solutions and 2.2% from Other

Syneos Health revenue breakdown by geographic segment: 64.7% from North America, 24.6% from Europe, Middle East and Africa and 10.8% from Asia-Pacific

Human Capital Metrics

Embed Graph
Show all human capital metrics

Syneos Health Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Syneos Health Online and Social Media Presence

Embed Graph

Syneos Health News and Updates

Syneos Health Acquires StudyKIK

Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Rete…

Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention

Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research

Novan Engages Syneos Health as Commercial Solutions Provider for SB206

– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients with molluscum contagiosum –

Syneos Health to Present at the 2021 Baird Global Healthcare Conference

MORRISVILLE, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the 2021 Baird …

Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization

Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies
Show more

Syneos Health Blogs

Unlocking Unprecedented Value: The Advent of the Established Brand

This webinar will uncover how you can plan and implement a strategy to support established brands into their maturity with great success.   In this session, you will:  Understand the evolution of

Syneos Health Podcast: 30 Years of Physician Answers

Discussing the value of longitudinal data, the impact COVID-19 has had on physician preferences and how companies can leverage this information to right-size their promotional efforts with agility in

Established Brands

In-Person and Remote Detailing Data from AnswerSuite Indicates Hybrid Model is Here to Stay

Syneos Health HCP Insight Offering Reveals Average Detail Minutes Have Increased Since Start of COVID-19 Pandemic    MORRISVILLE, N.C. – September 13, 2021 – AnswerSuite, a Syneos He

Paving a Site Contracting and Payment Pathway

In this white paper, our experts examine how the COVID-19 pandemic has impacted site contract and payment processes for study sponsors and what it will mean for them moving forward.

Trial Master File: Gaining a Competitive Advantage for Inspection Readiness

The evolving regulatory environment is causing transformation of Trial Master File (TMF) Management and Oversight. Regulatory authorities are now more focused on active TMF Management. This has result
Show more

Syneos Health Frequently Asked Questions

  • When was Syneos Health founded?

    Syneos Health was founded in 1998.

  • Who are Syneos Health key executives?

    Syneos Health's key executives are Alistair Macdonald, Jason Meggs and Neil Ferguson.

  • How many employees does Syneos Health have?

    Syneos Health has 25,000 employees.

  • What is Syneos Health revenue?

    Latest Syneos Health annual revenue is $4.4 b.

  • What is Syneos Health revenue per employee?

    Latest Syneos Health revenue per employee is $176.6 k.

  • Who are Syneos Health competitors?

    Competitors of Syneos Health include ICON, PPD and Worldwide Clinical Trials.

  • Where is Syneos Health headquarters?

    Syneos Health headquarters is located at 1030 Sync St, Morrisville.

  • Where are Syneos Health offices?

    Syneos Health has offices in Morrisville, Austin, Blue Bell, Boston and in 77 other locations.

  • How many offices does Syneos Health have?

    Syneos Health has 88 offices.